Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 232 entries
View as:

VX-950 and Peginterferon for Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT00251199 Org: User:
Start: 10/31/05 End: 03/31/06 Due: 03/31/07

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03227471 Org: User:
Start: 01/23/17 End: 03/27/18 Due: 03/27/19

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Phase: N/A Priority: Normal
NCT ID: NCT02390219 Org: User:
Start: 03/31/15 End: 10/31/16 Due: 10/31/17

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Phase: N/A Priority: Normal
NCT ID: NCT06832410 Org: User:
Start: 03/31/25 End: 09/17/27 Due: 09/17/28

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05867147 Org: User:
Start: 04/26/23 End: 06/14/23 Due: 06/14/24

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

Phase: N/A Priority: Normal
NCT ID: NCT06861413 Org: User:
Start: 04/01/25 End: 05/05/25 Due: 05/05/26

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01467492 Org: User:
Start: 01/31/12 End: 05/31/14 Due: 05/31/15

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

Phase: N/A Priority: Normal
NCT ID: NCT06508762 Org: User:
Start: 07/26/24 End: 09/10/24 Due: 09/10/25

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01511432 Org: User:
Start: 01/31/12 End: 07/31/12 Due: 07/31/13

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Phase: N/A Priority: Normal
NCT ID: NCT04353817 Org: User:
Start: 06/19/20 End: 05/17/21 Due: 05/17/22

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Phase: N/A Priority: Normal
NCT ID: NCT04969224 Org: User:
Start: 10/12/21 End: 07/26/22 Due: 07/26/23

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT06628908 Org: User:
Start: 10/01/24 End: 05/31/27 Due: 05/31/28

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT01590459 Org: User:
Start: 04/30/12 End: 07/31/14 Due: 07/31/15

Rollover Study of VX-770 in Cystic Fibrosis Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01117012 Org: User:
Start: 07/31/10 End: 05/31/14 Due: 05/31/15

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Phase: N/A Priority: Normal
NCT ID: NCT05535959 Org: User:
Start: 09/15/22 End: 11/09/22 Due: 11/09/23

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT01038167 Org: User:
Start: 01/31/10 End: 04/30/10 Due: 04/30/11

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05274269 Org: User:
Start: 05/09/22 End: 07/05/23 Due: 07/05/24

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Phase: N/A Priority: Normal
NCT ID: NCT05661734 Org: User:
Start: 01/09/23 End: 12/12/23 Due: 12/12/24

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Phase: N/A Priority: Normal
NCT ID: NCT06312787 Org: User:
Start: 04/02/24 End: 05/04/24 Due: 05/04/25

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT00953706 Org: User:
Start: 09/30/09 End: 05/31/13 Due: 05/31/14

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT06154447 Org: User:
Start: 12/12/23 End: 02/05/26 Due: 02/05/27

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Phase: N/A Priority: Normal
NCT ID: NCT05111145 Org: User:
Start: 01/14/22 End: 12/20/22 Due: 12/20/23

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02565914 Org: User:
Start: 08/31/15 End: 12/05/22 Due: 12/05/23

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Phase: N/A Priority: Normal
NCT ID: NCT04977336 Org: User:
Start: 07/19/21 End: 03/04/22 Due: 03/04/23

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00958152 Org: User:
Start: 08/31/09 End: 01/31/10 Due: 01/31/11